Showing results (121-130 of 156) with videos related to
Sort By:
Pageof 16
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2021
Long-term Follow-up and Patterns of Response, Progression, and Hyperprogression in Patients after PD-1 Blockade in Advanced SarcomaNicholas D Klemen, Sinchun Hwang, Martina Bradic, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2017
Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled AnalysisSandra P D'Angelo, James Larkin, Jeffrey A Sosman, et al.Nature Communications|September 8, 2022
Biomarker correlates with response to NY-ESO-1 TCR T cells in patients with synovial sarcomaAlexandra Gyurdieva, Stefan Zajic, Ya-Fang Chang, et al.Journal for Immunotherapy of Cancer|September 5, 2025
High transposable element expression in sarcomas is associated with increased immune infiltrates and improved outcomes including after immunotherapyBenjamin A Nacev, Martina Bradic, Hyung Jun Woo, et al.The Oncologist|May 30, 2013
Ipilimumab for patients with advanced mucosal melanomaMichael A Postow, Jason J Luke, Mark J Bluth, et al.The Oncologist|October 10, 2015
A Phase Ib/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib for the Neoadjuvant Treatment of Soft Tissue SarcomasRodrigo R Munhoz, Sandra P D'Angelo, Mrinal M Gounder, et al.ESMO Open|July 27, 2025
A phase I study of the CSF1R inhibitor vimseltinib in combination with the PD-L1 inhibitor avelumab in patients with advanced sarcomaE Rosenbaum, K Seier, M Bradic, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 23, 2019
Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophagesC A Gomez-Roca, A Italiano, C Le Tourneau, et al.Cancer Discovery|June 13, 2018
Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 c259T Cells in Synovial SarcomaSandra P D'Angelo, Luca Melchiori, Melinda S Merchant, et al.JAMA Oncology|January 24, 2020
Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab: A Phase 2 Clinical TrialCiara M Kelly, Cristina R Antonescu, Timothy Bowler, et al.Pageof 16